EDITAS MEDICINE INC
EDITNASDAQTrading Snapshot
- Day Range
- $2.90 – $2.95
- 52-Week Range
- $1.66 – $4.54
- Volume
- $2.80B
- Avg Volume
- $2.52B
- Shares Outstanding
- 153.5M
- Next Earnings
- Oct 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $41M
- Last Q Revenue
- $12M
- P/E Ratio
- -3.9
- P/S Ratio
- 9.6x
- EPS (TTM)
- $-0.62
- Dividend Yield
- 0.00%
Why Investors Own EDIT
- ✓High-growth profile — revenue up +58.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 74% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About EDITAS MEDICINE INC
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Editas Medicine (NASDAQ:EDIT) Beats Q2 Estimates, but One-Time Revenue Boost Masks Underlying Momentum
Editas Medicine beat Q2 estimates, but revenue surge was one-time; focus remains on EDIT-401 gene editing program.
Editas Medicine Q2 EPS $(0.15) Beats $(0.27) Estimate, Sales $11.900M Beat $2.800M Estimate
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.27) by 44.44 percent. This is a 76.19 percent increase over losses of $(0.63) per share from